Literature DB >> 23454516

Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.

Daniel M Heinrich1, Jack U Flanagan, Stephen M F Jamieson, Shevan Silva, Laurent J M Rigoreau, Elisabeth Trivier, Tony Raynham, Andrew P Turnbull, William A Denny.   

Abstract

High expression of the aldo-keto reductase enzyme AKR1C3 in the human prostate and breast has implicated it in the development and progression of leukemias and of prostate and breast cancers. Inhibitors are thus of interest as potential drugs. Most inhibitors of AKR1C3 are carboxylic acids, whose transport into cells is likely dominated by carrier-mediated processes. We describe here a series of (piperidinosulfonamidophenyl)pyrrolidin-2-ones as potent (<100 nM) and isoform-selective non-carboxylate inhibitors of AKR1C3. Structure-activity relationships identified the sulfonamide was critical, and a crystal structure showed the 2-pyrrolidinone does not interact directly with residues in the oxyanion hole. Variations in the position, co-planarity or electronic nature of the pyrrolidinone ring severely diminished activity, as did altering the size or polarity of the piperidino ring. There was a broad correlation between the enzyme potencies of the compounds and their effectiveness at inhibiting AKR1C3 activity in cells.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454516     DOI: 10.1016/j.ejmech.2013.01.047

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

1.  Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.

Authors:  Adegoke Adeniji; Md Jashim Uddin; Tianzhu Zang; Daniel Tamae; Phumvadee Wangtrakuldee; Lawrence J Marnett; Trevor M Penning
Journal:  J Med Chem       Date:  2016-08-12       Impact factor: 7.446

2.  Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

Authors:  Tianzhu Zang; Kshitij Verma; Mo Chen; Yi Jin; Paul C Trippier; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2014-12-31       Impact factor: 5.192

Review 3.  Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.

Authors:  Trevor M Penning
Journal:  Expert Opin Ther Pat       Date:  2017-09-19       Impact factor: 6.674

4.  In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.

Authors:  Jovana J Plavša; Pavlína Řezáčová; Michael Kugler; Petr Pachl; Jiří Brynda; Zdeněk Voburka; Anđelka Ćelić; Edward T Petri; Jana Škerlová
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2018-04-24       Impact factor: 1.056

Review 5.  Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy.

Authors:  Chen-Ming Zeng; Lin-Lin Chang; Mei-Dan Ying; Ji Cao; Qiao-Jun He; Hong Zhu; Bo Yang
Journal:  Front Pharmacol       Date:  2017-03-14       Impact factor: 5.810

6.  Synthesis and molecular docking studies of some 4-phthalimidobenzenesulfonamide derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.

Authors:  Zeynep Soyer; Sirin Uysal; Sulunay Parlar; Ayse Hande Tarikogullari Dogan; Vildan Alptuzun
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-21       Impact factor: 5.051

Review 7.  Intracrine androgen biosynthesis and drug resistance.

Authors:  Trevor M Penning; Irfan A Asangani; Cynthia Sprenger; Stephen Plymate
Journal:  Cancer Drug Resist       Date:  2020-11-03

8.  AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638.

Authors:  Wen Zhou; Patrizia Limonta
Journal:  Front Oncol       Date:  2014-06-23       Impact factor: 6.244

9.  The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.

Authors:  Yarong Diana Yin; Melissa Fu; Darby G Brooke; Daniel M Heinrich; William A Denny; Stephen M F Jamieson
Journal:  Front Oncol       Date:  2014-06-18       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.